PDF(Pubmed)
Abstract：
Rapamycin is an mTOR inhibitor that has been shown to extend the lifespan of laboratory model organisms. In humans, rapamycin is used at higher doses as an immunosuppressive medication to prevent organ rejection. Numerous adverse effects are seen with rapamycin treatment in humans, with one of the most common being dysregulation of lipid metabolism. In humans, this often manifests as mild to moderate serum lipid elevations, with a small subset developing extreme triglyceride elevations. This case report describes an eight-year-old, castrated male, clinically healthy Labrador retriever who developed severe hypertriglyceridemia associated with low-dose rapamycin administration over a six-month period. During this time, the dog was asymptomatic and displayed no other clinical abnormalities, aside from a progressive lipemia. Within 15 days of discontinuing rapamycin treatment, and with no targeted lipemic intervention, the dog\'s lipemia and hypertriglyceridemia completely resolved.
摘要：
雷帕霉素是一种mTOR抑制剂，已被证明可以延长实验室模型生物的寿命。在人类中,雷帕霉素在较高剂量下用作免疫抑制药物以防止器官排斥。在人类中雷帕霉素治疗可以看到许多副作用，其中最常见的是脂质代谢失调。在人类中,这通常表现为轻度至中度的血脂升高，一小部分人发展出极端的甘油三酯升高。这个病例报告描述了一个八岁的孩子,阉割的男性，临床健康的拉布拉多猎犬在6个月内出现与低剂量雷帕霉素给药相关的严重高甘油三酯血症。在此期间,这只狗无症状，没有其他临床异常，除了进行性脂血.在停止雷帕霉素治疗的15天内，没有针对性的血脂干预，狗的血脂和高甘油三酯血症完全解决。
